Markers for individualised therapy in endometrial carcinoma
Authors:
- Helga B SalvesenHSHelga B Salvesen
- Ingfrid S HaldorsenIHIngfrid S Haldorsen
- Jone TrovikJTJone Trovik
Top Cited Papers
- 1 August 2012
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 13 (8) , e353-e361
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA MutationsJournal of Clinical Oncology, 2012
- Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometriumAnnals of Oncology, 2011
- Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials GroupJournal of Clinical Oncology, 2011
- A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker CodevelopmentJNCI: Journal of the National Cancer Institute, 2009
- Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activationProceedings of the National Academy of Sciences, 2009
- Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysisThe Lancet, 2009
- Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised studyThe Lancet, 2009
- Drug-sensitiveFGFR2mutations in endometrial carcinomaProceedings of the National Academy of Sciences, 2008
- Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activityProceedings of the National Academy of Sciences, 2007
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001